RHINOMED
MAKE EVERY BREATH COUNT

RHINOMED'S NEW NASAL SWAB SUCCESSFULLY REGISTERED WITH US FDA

20 November 2020 Melbourne, Australia.
Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in nasal airway and respiratory technology, is pleased to announce that it has successfully registered its novel nasal swab with the US FDA as a Class 1 device to collect samples from the nose to detect upper respiratory tract diseases including influenza and coronavirus strains.

The successful registration and conformity with the relevant standards means that Rhinomed's novel nasal swab is now able to be sold in the US market.

The new nasal swab is an extension of Rhinomed's nasal technology platform and intellectual property patent portfolio using the company's depth of experience as a world-leading developer of nasal devices. Rhinomed's existing nasal products have been worn comfortably and safely since 2016 and are sold in more than 20,000 pharmacies worldwide.

Rhinomed's nasal swab is:

- Less invasive and more comfortable than standard nasopharyngeal swabs;
- Unique as it collects samples from both nostrils simultaneously.
- Able to collect samples from a far greater surface area of the nose than normal swabs;
- Able to be self-administered easily, anywhere, reducing the risk of infection of healthcare workers; and
- Able to be used by a wide number of people every day.

Rhinomed's nasal swab is designed for self-collection in the home, workplace or in a clinical setting under supervision and is expected to address the problems with current nasopharyngeal swabs that are highly invasive and uncomfortable. Most existing nasal swabs require a healthcare worker to collect the sample, which places the healthcare worker at risk of infection. The use of healthcare workers and the requisite personal protection equipment (PPE) also comes with significant cost.

The new Rhinomed swab is designed to be able to collect a larger sample, be worn for a predetermined time (it remains snugly in place) and collect a sample from both nostrils simultaneously, thus offering the potential for a more effective diagnostic sample. The swab has been designed to fit into existing vials and work with existing pathology workflows.

The Company is now rapidly scoping manufacturing and is assessing additive manufacturing (3D printing) solutions, existing offshore manufacturing resources and assessing the viability of local manufacturing.

Rhinomed is advancing discussions with potential commercial partners in respect to the program. Further details on the clinical and commercial program will be announced as further progress occurs.

This announcement has been authorised for release by the Board.

Media Enquiries
Michael Johnson, CEO & Director
+61 (03) 8416 0900
mjohnson@rhinomed.global
Follow us on **Twitter** @rhinomedceo and @theturbinecom

Rudi Michelson, Monsoon Communications
+61 (0)411 402 737
rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne-based ASX-listed airway technology company that has developed a novel nasal and respiratory technology platform.

With its initial product Turbine, Rhinomed has established a leading position in emphasizing the role of breathing in sport and exercise. With its Mute variant, the company has also entered the sleep sector to tackle the global snoring market, while its third product, the Pronto range, tackles nasal congestion and sleep disturbance issues. The company is developing applications for the delivery of medical cannabis and for conditions including anxiety, pain, allergies, nausea, anxiety and coughs and colds.

Rhinomed's devices are sold in over 20,000 stores worldwide including Walgreens, CVS, Boots and online with Amazon; and are approved in major markets including the US, Europe, Canada and Australia.